CEACAM5 and neoplasm: Several serum tumour markers are currently under evaluation, however, carcinoembryonic antigen (CEA) is the only one in regular clinical use for determining prognosis, for surveillance following curative resection and for monitoring therapy in advanced disease [1-4].